Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMEV-Applied Molecular Evolution -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (14)	10/18/2001 4:46:24 PM
From: nigel bates	Read Replies (2) \| Respond to of 164

From the MEDI 3rd Qtr statement (FWIW) - "...Finally, we have been making substantial progress in research and development. During the first nine months of 2001: we initiated nine new clinical studies and completed enrollment in ten; presented clinical data on siplizumab at two international psoriasis meetings; received FDA's approval to produce Synagis with our proprietary Enhanced Yield Process that quadruples fermentation yields; and made tremendous progress with our preclinical anti-asthma IL-9 program...''